# US 2016/0354412 A1 · Use of cells derived from first trimester umbilical cord tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354412 A1
- Document ID: US20160354412A1
- Status: Published application
- Kind: A1
- Application number: 15/239,261
- Filed: 2016-08-17
- Published: 2016-12-08
- Earliest claimed: 2007-09-13
- Assignees: Reprobiogen Inc.
- Inventors: Clifford L. LIBRACH; Shangmian YIE; Rong XIAO
- Web page: https://patentgrep.com/patent/US20160354412A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 35/44: Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of isolating a pluripotent cell from human umbilical cord is described herein. The method involves collecting a sample of umbilical cord from fetal tissue obtained at less than 13 weeks of gestation, for example a first trimester umbilical cord. The sample is treated to obtain isolated umbilical cord cells, after which the isolated umbilical cord cells are incubated. Cells obtained in this way can be differentiated for use in treating conditions of cell damage, by supplanting the function of a damaged cell in a condition such as spinal cord injury, cardiovascular injury or heart disease.

## Claims

### Claim 1

A method of treating a condition of cellular damage, comprising supplanting the function of a damaged cell with a pluripotent cell from a human umbilical cord, wherein the pluripotent cell is obtained by:
collecting an umbilical cord from fetal tissue obtained at less than 13 weeks of gestation, by collecting fetal placenta tissue by surgical aspiration; and separating the umbilical cord from the fetal placenta tissue;
treating the umbilical cord to obtain isolated umbilical cord cells, by:
washing the umbilical cord with PBS,
cutting the umbilical cord, comprising an artery and two vessels, into smaller cut pieces,
treating the cut pieces with collagenase to obtain isolated umbilical cord cells, and
washing the isolated umbilical cord cells with PBS; and
incubating the isolated umbilical cord cells, by suspending the isolated umbilical cord cells in a maintenance medium comprising α-MEM, penicillin-streptomycin, and amphotericin; and
maintaining the isolated umbilical cord cells under appropriate growth conditions of 37° C., 5% CO2;
wherein prior to cutting the umbilical cord into smaller cut pieces, the umbilical cord is from 0.5-2.0 cm in length and comprises an artery;
wherein the isolated umbilical cord cells express one or more transcription factor associated with undifferentiated stem cells; and the transcription factor is OCT-4, SOX-2, or Nanog; and
wherein the condition of cellular damage is spinal cord injury, Parkinson's disease, Alzheimer's disease, cardiovascular injury, heart disease, stroke, burn, diabetes, osteoarthritis or rheumatoid arthritis.

### Claim 2 (depends on 1)

The method according to claim 1, wherein obtaining the pluripotent cell additionally comprises:
maintaining the isolated umbilical cord cells and changing the maintenance medium every 3-7 days;
freezing the isolated umbilical cord cells; and
thawing and restoring the isolated umbilical cord cells to viability.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the collagenase is Type I at 1 mg/mL.

### Claim 4 (depends on 1)

The method according to claim 1, wherein maintaining the isolated umbilical cord cells comprises:
washing the isolated umbilical cord cells with PBS;
adding trypsin-EDTA;
harvesting the isolated umbilical cord cells into a tube containing maintenance medium;
separating the isolated umbilical cord cells from the maintenance medium;
mixing the isolated umbilical cord cells with new maintenance medium;
diluting the new maintenance medium containing the isolated umbilical cord cells with additional maintenance medium to obtain a diluted maintenance medium containing the isolated umbilical cord cells; and
maintaining the diluted maintenance medium containing the isolated umbilical cord cells under appropriate growth conditions of 37° C., 5% CO2 and changing the maintenance medium every 3-7 days.

### Claim 5 (depends on 2)

The method according to claim 2, wherein freezing the isolated umbilical cord cells comprises:
washing the isolated umbilical cord cells with PBS;
adding trypsin-EDTA;
harvesting the isolated umbilical cord cells into a tube containing maintenance medium;
separating the isolated umbilical cord cells from the maintenance medium; cooling the isolated umbilical cord cells to 4° C.;
mixing the isolated umbilical cord cells with a freezing medium at 4° C., said freezing medium comprising DMSO;
transferring the freezing medium containing the isolated umbilical cord cells to vials pre-chilled to −70° C.;
storing the vials at −70° C. for 24 h; and
storing the vials in liquid nitrogen.

### Claim 6 (depends on 2)

The method according to claim 2, wherein thawing and restoring the isolated umbilical cord cells comprises:
warming the vials 37° C.;
separating the isolated umbilical cord cells from the freezing medium;
mixing the isolated umbilical cord cells with maintenance medium;
maintaining the maintenance medium containing the isolated umbilical cord cells under appropriate growth conditions of 37° C. , 5% CO2, for 24 hours;
replacing the maintenance medium with new maintenance medium; and
maintaining the new maintenance medium containing the material under appropriate growth conditions, said conditions being 37° C. , 5% CO2 and changing the new maintenance medium every 3-7 days.

### Claim 7 (depends on 1)

The method according to claim 1, wherein maintaining the isolated umbilical cord cells comprises: (i) aspirating the medium from the cells when the density of cells exceeds about 70% of the surface of a culture dish or flask in which the cells are maintained, (ii) washing the cells with PBS; (iii) adding trypsin-EDTA to cover the cells until the cells lift off of the dish or flask; and (iv) resuspending the cells in maintenance medium.

### Claim 8 (depends on 1)

The method of claim 1, wherein the damaged cell is supplanted by the pluripotent cell differentiated to a neuronal cell, an osteoblast, a chondrocyte, a myocyte, an adipocyte, or a β-pancreatic islet cell.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pluripotent cell is differentiated to a neuronal cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein the condition comprises spinal cord injury, Parkinson's disease or Alzheimer's disease.

### Claim 11 (depends on 10)

The method of claim 10, wherein the condition is spinal cord injury.

### Claim 12 (depends on 8)

The method of claim 8, wherein the pluripotent cell is differentiated to a cardiomyocyte.

### Claim 13 (depends on 12)

The method of claim 12, wherein the condition is cardiovascular injury or heart disease.
